Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals
2005 FOUNDED
PUBLIC STATUS
81-90 EMPLOYEES
ACRX STOCK SYMBOL
$1.84 SHARE PRICE (As of Wednesday Closing)
Description

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

Website
Formerly Known As
Surx
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 351 Galveston Drive
  • Redwood City, CA 94063
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AcelRx Pharmaceuticals’s full profile, request a free trial.

AcelRx Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.64 - $4.09 $146M $1.80 -$0.67 865K 79.6M

AcelRx Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 111,980 127,052 56,404 46,731
Revenue 2,427 2,151 7,995 17,357
EBITDA (48,897) (35,152) (36,938) (29,905)
Net Income (51,375) (47,149) (51,508) (43,157)
Total Assets 104,978 120,533 75,552 99,993
Total Debt 28,841 11,991 19,096 21,549
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AcelRx Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore AcelRx Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

AcelRx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore AcelRx Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

AcelRx Pharmaceuticals Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evoke Pharma Formerly VC-backed Solana Beach, CA 0 0000 00000000000 0000
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0
00000000 Venture Capital-Backed San Francisco, CA 0000 00000000000 0000
000000 Formerly VC-backed Mountain View, CA 00 00000 000000&0 00000
000000 Corporation North Chicago, IL 000000 000.00 000000000 000.00
To view this company’s complete list of competitors, request access »

AcelRx Pharmaceuticals Executive Team (18)

Name Title Board
Seat
Contact
Info
Meera Desai Ph.D Director, Alliance Management and Corporate Development
Vincent Angotti Chief Executive Officer & Board Member
Raffi Asadorian Chief Financial Officer & Chief Accounting Officer
Larry Hamel Chief Development Officer
Badri Dasu Executive

10 Former Executives

You’re viewing 5 of 18 executives. Get the full list »

AcelRx Pharmaceuticals Board Members (11)

Name Representing Role Since Contact
Info
Adrian Adams Self Chairman & Board Member 000 0000
Howard Rosen AcelRx Pharmaceuticals Board Member 000 0000
Mark Edwards Self Board Member 000 0000
Mark Wan Three Arch Partners Board Member 000 0000
Richard Afable MD Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »